This post was originally published on this site AstraZeneca‘s Imfinzi (durvalumab) continues to demonstrate superior overall survival compared to placebo when given to patients with stage III, inoperable non-small-cell lung cancer (NSCLC) whose disease did not progress after platinum-based chemotherapy and radiation therapy. That finding comes from the three-year data update of the company’s randomized, blinded PACIFIC Phase 3…
This post was originally published on this site End-of-study data from the CLEOPATRA trial supports the long-term efficacy of Genentech‘s Perjeta (pertuzumab) plus Herceptin (trastuzumab) and docetaxel chemotherapy for patients with previously untreated HER2-positive metastatic breast cancer. Patients on the Perjeta combination regimen lived a median 16.3 months longer, compared with the control group not receiving Perjeta,…
This post was originally published on this site The immune checkpoint molecules PD-L1 and TIM-3 have prognostic value in people with ovarian cancer who have not yet received chemotherapy. But while low levels of TIM-3 were linked to longer survival rates, a study unexpectedly showed that high levels of PD-L1 predicted better patient survival. The…
This post was originally published on this site An under-the-skin formulation of daratumumab is as effective as its intravenous delivery — marketed as Darzalex — at easing tumor burden and has comparable safety in adults with relapsed or refractory multiple myeloma, according to a Phase 3 trial. Trial results were presented in a study, “Efficacy…
This post was originally published on this site Seattle Genetics‘ Adcetris (brentuximab vedotin) in combination with standard chemotherapy continues to show better clinical activity than bleomycin plus standard chemotherapy, as a front-line treatment for patients with Hodgkin’s lymphoma, updated Phase 3 data shows. Three-year data from the company’s randomized, open-label ECHELON-1 Phase 3 trial (NCT01712490) was…
This post was originally published on this site Treatment with Xtandi (enzalutamide) and testosterone suppression prolonged the survival of men with metastatic hormone-sensitive prostate cancer in comparison with standard of care, according to early findings of a large Phase 3 trial. The study, “Overall survival (OS) results of a phase III randomized trial of standard-of-care…
This post was originally published on this site A single infusion of KTE-X19, Kite Pharma‘s investigational CD19 CAR-T cell therapy, leads to high response rates in patients with relapsed or refractory acute lymphoblastic leukemia (ALL), Phase 1/2 trial data show. The findings were presented during an oral session titled, “End of phase I results of…
This post was originally published on this site Scientists have created a new artificial intelligence (AI)-based model that outperforms current models at predicting the risks a woman has of developing breast cancer, and works equally well in white and African American women. The findings of the study, “A Deep Learning Mammography-based Model for Improved Breast…
This post was originally published on this site Adding Erleada (apalutamide), Janssen‘s next-generation androgen receptor inhibitor, to androgen deprivation therapy (ADT) can prolong life and extend the time without disease worsening in men with metastatic castration-sensitive prostate cancer, a Phase 3 trial shows. The findings — which supported Janssen’s application to the U.S. Food and…
This post was originally published on this site Lynparza (olaparib), given to advanced ovarian cancer patients with BRCA mutations who were previously treated with at least two lines of platinum chemotherapy, had significantly better response rates and progression-free survival times than those given chemotherapy, full results from the SOLO-3 Phase 3 trial show. These findings make…
